- Of the 12 Phase 1b patients evaluable for efficacy as of the ASCO-GI data cut-off date (November 1, 2020), 5 (42%) achieved a partial response (PR) and 8 (67%) have shown a durable response ranging from 6.1 to 13.7 months

-- Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in evaluable patients in cohorts A and B. Patients eligible for the trial have two consecutive rises in PSA levels indicating initial resistance to abiraterone (Zytiga®)

-10 of 11 (91%) patients achieved disease control (SD - stable disease plus PR - partial response) with only 1 patient progressing in <6 months while on treatment

- Virtual event will take place on Wednesday, Sept. 23, 2020 at 11 a.m. EDT and will include a Q&A session